scispace - formally typeset
Search or ask a question
Topic

Psychotropic drug

About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: In this article, the authors assess the prevalence of alcohol, tobacco and psychotropic drug consumption by students of the Medical School of the Federal University of Minas Gerais, Brazil, and verify aspects related to those addictions.
Abstract: Objective The purpose of this study was to assess the prevalence of alcohol, tobacco and psychotropic drug consumption by students of the Medical School of the Federal University of Minas Gerais, Brazil, and to verify aspects related to those addictions. Methods This study was carried out with students of all years of the medical course invited to participate anonymously, by answering a self-applied questionnaire which was previously evaluated and adapted to Brazilian reality. It was based upon the World Health Organization's Guidelines for Student Substance Use Survey and included 25 questions about drug addiction. Student's t test and chi-square test were applied to assess differences between the mean and proportions of data. Results Alcohol and tobacco were the more frequently used by the students, 85.2% and 16.3% respectively. Among psychotropic drugs, marijuana was reported by 16.5% of students, LSD by 6.9%, sedatives by 12%, amphetamines by 7.5% and inhalant substances by 16.8%. Cocaine, crack, opiates, anticholinergics and anabolics consumption were rarely mentioned. Conclusion Alcohol was the drug most used and was related to other drug addictions. Drugs were most frequently used by single, male students, who live alone and do not support themselves.

21 citations

Journal ArticleDOI
TL;DR: To determine the current prevalence of psychotropic drug use by women and any association between use and demographic variables, a cross‐sectional, questionnaire‐based survey is conducted.
Abstract: OBJECTIVE To determine the current prevalence of psychotropic drug use by women and any association between use and demographic variables. DESIGN A cross-sectional, questionnaire-based survey. SETTING Metropolitan Melbourne between November 1993 and February 1994. SUBJECTS Consecutive women aged over 18, attending 15 randomly selected general practices for a consultation. OUTCOME MEASURES Psychotropic drugs taken in the last year and duration of their use, reported by the doctor from the patients' clinical notes and patient interview. Patient demographic characteristics. RESULTS The questionnaire was returned complete for 2048/3026 women. Of these, 20.4% had taken at least one psychotropic drug for at least a month in the past year. Most of these women had taken the drug for longer than 12 months and a quarter had taken more than one psychotropic drug in the past year. Psychotropic drug use by women was significantly associated with increasing age, having been married, parity, lower educational attainment, manual occupation, unemployment and being supported by a government pension. CONCLUSIONS Psychotropic drug use by women is common and mostly long term. Psychotropic drugs should be prescribed carefully and judiciously, with continual review of the indications for their use and with an awareness of the association with social situation.

21 citations

Journal ArticleDOI
TL;DR: Delayed arrival from ingestion, a low level of unconsciousness, and a sign of circulatory insufficiency in a patient with a psychotropic drug overdose were risk factors of a delayed recovery and death.
Abstract: Purpose The aim of this study was to investigate which factors on arrival correlate with the duration of unconsciousness induced by a psychotropic drug overdose. Basic Procedure Patients were 175 consecutive intubated patients unconscious due to psychotropic drug overdose. They were divided into 2 groups, an "early" group in which the patients were extubated within 2 days from hospitalization, and a "delayed" group who were not extubated within 2 days. Main Findings Glasgow Coma Scale ( P = .001) scores in the early group were higher than those in the delayed group. The estimated time from ingestion to admission ( P P P P P = .001) in the early group were smaller than those in the delayed group. Two subjects in the delayed group died of pneumonia and pulmonary embolism. Principal Conclusions Delayed arrival from ingestion, a low level of unconsciousness, and a sign of circulatory insufficiency in a patient with a psychotropic drug overdose were risk factors of a delayed recovery and death.

21 citations

Journal Article
TL;DR: It is postulated that SR 95191 is a selective and reversible type A MAOI of medium potency, which may be of therapeutic benefit in depressed patients and did not affect monoamine uptake either in vitro or in vivo.
Abstract: SR 95191 [3-(2-morpholino-ethyl-amino)-4-cyano-6-phenylpyridazine] is a novel psychotropic drug which possesses the pharmacological properties of a selective, reversible type A monoamine oxidase inhibitor (MAOI). The MAOI activity of SR 95191 was examined in the rat brain, liver and duodenum and compared to that of clorgyline, harmaline, l-deprenyl, moclobemide and cimoxatone. In vitro, SR 95191 selectively inhibited MAO-A and was less potent than cimoxatone, clorgyline and harmaline, but was more potent than moclobemide. Ex vivo, SR 95191 also preferentially inhibited MAO-A in the brain and was 6 and 13 times less potent than cimoxatone and moclobemide, respectively. Like all MAO-A inhibitors, SR 95191 in vivo caused a dose-dependent increase in striatal 3-methoxytyramine, dopamine, serotonin and in hypothalamic norepinephrine contents. A concomitant decrease in deaminated metabolites was observed. SR 95191 inhibited peripheral MAO activity in liver and duodenum. In brain, liver and duodenum, MAO inhibition induced by SR 95191 was short-lasting. Repeated dosing for 14 days did not enhance MAO-A inhibition. Like all reversible MAOIs, SR 95191 antagonized the long-lasting MAO-A inhibition induced by clorgyline. Finally, SR 95191 did not affect monoamine uptake either in vitro or in vivo and did not interact in vitro with a variety of neurotransmitter or drug receptor sites. Based on these results it is postulated that SR 95191 is a selective and reversible type A MAOI of medium potency, which may be of therapeutic benefit in depressed patients.

21 citations

Journal ArticleDOI
TL;DR: The results indicate a binding site heterogeneity consistent with the labelling of both 5-HT and dopamine (DA) receptors by [ 3 H]-spiperone both in vitro and in vivo.

21 citations


Network Information
Related Topics (5)
Schizophrenia
38.2K papers, 1.6M citations
86% related
Anxiety disorder
17.6K papers, 1.3M citations
86% related
Comorbidity
26.8K papers, 1.4M citations
82% related
Anxiety
141.1K papers, 4.7M citations
81% related
Mental health
183.7K papers, 4.3M citations
81% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
202332
202268
202175
202058
201960
201876